November 20, 2014

Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.

October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

October 17, 2014

Purdue Pharma has launched an awareness campaign to address specific knowledge gaps among pharmacists related to its Schedule III extended-release transdermal opioid, Butrans.

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

October 9, 2014

Purdue Pharma on Thursday announced the launch of a new dosage strength of 7.5 mcg/hour for its Butrans (buprenorphine) transdermal system CIII, bringing the total number of strengths offered by the company to five.

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

September 30, 2014

Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. 

September 26, 2014

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. 

September 24, 2014

Dr. Reddy's Labs on Wednesday announced the launch of levalbuterol inhalation solution, USP in 0.31-mg, 0.63-mg and 1.25-mg unit-dose vials.

September 16, 2014

The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.

September 5, 2014

Purdue Pharma on Thursday presented results from two epidemiological studies evaluating the reformulation of OxyContin. 

August 25, 2014

DSN presents a preview of some of the hottest beauty products that appear on the show floor at NACDS Total Store Expo.

August 25, 2014

DSN presents a preview of some of the hottest OTC products that appear on the show floor at NACDS Total Store Expo.

August 23, 2014

DSN presents a preview of some of the hottest beauty products that appear on the show floor at NACDS Total Store Expo.

August 23, 2014

DSN presents a preview of some of the hottest OTC products that appear on the show floor at NACDS Total Store Expo.

August 18, 2014

Patients with low blood levels of vitamin D are at increased risk of death and serious complications after noncardiac surgery, according to a study published Friday in Anesthesia & Analgesia.

August 14, 2014

Amneal Pharmaceuticals announced four new additions to its portfolio of generic drugs, which represent multiple therapeutic categories and account for $900 million annually in U.S. sales, the company said, citing data from IMS Health.

August 5, 2014

Lannett Co. on Monday announced that its abbreviated new drug application for oxycodone hydrochloride capsules, 5 mg, has been approved by the Food and Drug Administration.

August 4, 2014

Gummy vitamins continues to be a fast-moving subsegment within multivitamins, Jim Craigie, Church & Dwight executive chairman and CEO, told analysts Friday. 

July 24, 2014

Abbott, the makers of Similac, studied the diets of more than 80 lactating women to assess how their nutritional intake compared to dietary recommendations. In the study, only 1-of-10 breastfeeding moms on average got 100% of the desired levels for DHA, lutein and vitamin E from their diet.

July 24, 2014

The Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), a long-acting opioid analgesic.

July 17, 2014

Purdue Pharma announced that the Food and Drug Administration approved a new 7.5-mcg/hour dosage strength of Butrans (buprenorphine) transdermal system CIII.

July 14, 2014

Teva Pharmaceuticals on Monday announced that the Food and Drug Administration has accepted the company's new drug application for albuterol multi-dose dry-powder inhaler, a breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.

July 8, 2014

Mylan announced the launch of telmisartan tablets USP, which is used to treat hypertension.